Bibliographic Info
GuidelineWHO guidelines for malaria, 30 November 2024.
Year of Publication2024
Issuing InstitutionWHO
Recommendation
Status
Updated
Recommended in favor
Conditional
Certainty of evidence
Low
Tafenoquine is recommended as an alternative to primaquine (3.5 mg/kg total dose) for preventing relapses of P. vivax in patients ≥ 2years of age, who have ≥ 70% glucose-6-phosphate dehydrogenase (G6PD) activity and who receive chloroquine treatment.